Tag

Novo Nordisk

14 stories

Novo Targets FDA Filing for Etavopivat After 27% VOC Reduction

Etavopivat cut vaso-occlusive crisis rates by 27% in a 385-patient phase 3 trial, and Novo Nordisk is now targeting an FDA submission in the second half of…

Deals 2 days ago

UCB Paid $1.15B for Neurona's Single-Dose Epilepsy Cell Therapy

UCB paid up to $650m upfront, with up to $500m in future milestones, to buy Neurona Therapeutics in a deal valued at up to $1.15bn.

Deals 2 days ago

Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record

Kailera Therapeutics priced just under 40 million shares at $16 apiece Friday, pulling in $625 million on its Nasdaq debut under KLRA.

Deals 3 days ago

Kailera Prices $625m IPO, One of the Largest Biotech Offerings Since Moderna 2018

Kailera Therapeutics priced its IPO at $625m, or $16 a share, on April 16 — at the top of its S-1 range and one of the largest biotech public offerings…

Deals 3 days ago

Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018

Kailera Therapeutics priced its IPO at $16 a share Friday, raising $625 million, the largest biotech public offering in recent memory, topping Moderna's…

FDA 5 days ago

FDA Cleared Foundayo With 3 Postmarketing Safety Study Requirements

FDA cleared Foundayo, Eli Lilly's oral GLP-1 pill for obesity, on April 1, but the approval letter lists three postmarketing requirements tied to what the…

FDA Apr 13, 2026

FDA Cleared Foundayo; Lilly Pre-Stocked $1.5B Before Approval

FDA cleared Foundayo eight days ago, and Eli Lilly was ready: the company pre-stocked $1.5 billion worth of the pill back in February, months before…

Deals Apr 10, 2026

Novo Loses GLP-1 Pioneer Lotte Bjerre Knudsen to Retirement

Novo Nordisk is losing a key obesity figure.

FDA Apr 8, 2026

Lilly's Foundayo Clears FDA; Novo's Oral Wegovy Holds 5-Point Efficacy Lead

Lilly's oral obesity pill approved but trails Novo on weight loss. Pharma's M&A sprint added $7.9B in deals and Trump's tariffs landed with carveouts.

FDA Apr 7, 2026

Novo Nordisk's 7.2 mg Wegovy Hits US Shelves at Triple the Standard Dose

Novo Nordisk's 7.2 mg Wegovy is now available in the US, tripling the standard 2.4 mg dose in a direct bid to reclaim ground lost to Lilly's Zepbound.

Deals Apr 6, 2026

Anthropic Pays $400M for a 10-Person Ghost Company

Anthropic is paying ~$400M for Coefficient Bio, a sub-10-person stealth startup. The price signals how expensive life sciences AI talent has become.

FDA Apr 5, 2026

Novo Fires Back at Lilly's Foundayo With Competing Efficacy Data

Novo Nordisk published rival efficacy data the day after FDA approved Lilly's oral obesity pill Foundayo — but no head-to-head trial exists to back the claims.

FDA Apr 5, 2026

FDA Clears Novo Nordisk's Higher-Dose Wegovy in 54 Days

FDA approved Novo Nordisk's 7.2mg Wegovy HD in 54 days via the CNPV fast-track, handing Novo a pricing lever and leaving insurers to argue the math.

FDA Apr 5, 2026

FDA Clears 7.2mg Wegovy HD for Novo Nordisk in 54-Day Sprint

FDA cleared Novo Nordisk's 7.2mg Wegovy HD in 54 days under its national priority program, pushing the GLP-1's efficacy ceiling higher.